Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Accured Expenses (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Change in Accured Expenses for 15 consecutive years, with -$19.2 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Accured Expenses rose 26.57% year-over-year to -$19.2 million; the TTM value through Mar 2026 reached $6.1 million, up 240.66%, while the annual FY2025 figure was -$790000.0, 121.39% down from the prior year.
  • Change in Accured Expenses hit -$19.2 million in Q1 2026 for Agios Pharmaceuticals, down from $8.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $14.5 million in Q2 2025 and bottomed at -$26.1 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is -$297764.7, with a median of $1.4 million recorded in 2022.
  • Year-over-year, Change in Accured Expenses surged 2034.18% in 2023 and then plummeted 364.03% in 2024.
  • Agios Pharmaceuticals' Change in Accured Expenses stood at $594000.0 in 2022, then soared by 2034.18% to $12.7 million in 2023, then rose by 6.92% to $13.6 million in 2024, then tumbled by 34.68% to $8.9 million in 2025, then tumbled by 316.47% to -$19.2 million in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$19.2 million, $8.9 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.